Boyounuo is a biosimilar approved by the National Medical Products Administration (NMPA) in accordance with Technical Guidelines for Evaluation on Similarities and Extrapolation of Indications of Biosimilars promulgated in February 2021.
(This product is a prescription drug, please take this drug with doctor’s prescription and under doctor’s instruction)
Different from chemotherapy that directly attack cancer cells, Bevacizumab functions by blocking blood supply to a tumor, so as to inhibit its growth.
Vascular endothelial growth factor (VEGF) promotes angiogenesis by inducing proliferation of endothelial cells. With overexpression of VEGFs in diverse tumors, Bevacizumab blocks combination of free VEGFs and relevant receptors to inhibit neoplastic neovascularization. As tumor gets diminishing support in nutrition, it will be restrained from growth eventually.
1. Rini BI, Small EJ. J Clin Oncol 2005;23:1028-1043.
2. Ruba S. Darweesh, et al. International Journal of Nanomedicine. 2019,14:7643-7663.